Figure 4
Percentage of total CD28neg CD4pos T cells from anti-TNF-treated RA patients over time in patients receiving anti-tumor necrosis factor (TNF) treatments. Peripheral blood mononuclear cells (PBMCs) from RA patients were stained for CD28 and CD4, examined with flow cytometry, and the percentages were represented according to the responder/nonresponder clinical status of patients.